These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 32251365)

  • 1. Considering mutational meltdown as a potential SARS-CoV-2 treatment strategy.
    Jensen JD; Lynch M
    Heredity (Edinb); 2020 May; 124(5):619-620. PubMed ID: 32251365
    [No Abstract]   [Full Text] [Related]  

  • 2. Favipiravir, an antiviral for COVID-19?
    Coomes EA; Haghbayan H
    J Antimicrob Chemother; 2020 Jul; 75(7):2013-2014. PubMed ID: 32417899
    [No Abstract]   [Full Text] [Related]  

  • 3. Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis.
    Shannon A; Selisko B; Le NT; Huchting J; Touret F; Piorkowski G; Fattorini V; Ferron F; Decroly E; Meier C; Coutard B; Peersen O; Canard B
    Nat Commun; 2020 Sep; 11(1):4682. PubMed ID: 32943628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series.
    Fu D; Cao R; Zhao L; Li W; Zhong W; Wen J
    Crit Care; 2020 Sep; 24(1):578. PubMed ID: 32977854
    [No Abstract]   [Full Text] [Related]  

  • 5. Metabolomics to Predict Antiviral Drug Efficacy in COVID-19.
    Migaud M; Gandotra S; Chand HS; Gillespie MN; Thannickal VJ; Langley RJ
    Am J Respir Cell Mol Biol; 2020 Sep; 63(3):396-398. PubMed ID: 32574504
    [No Abstract]   [Full Text] [Related]  

  • 6. [Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?].
    Nisole S; Saulnier A; Gatignol A
    Virologie (Montrouge); 2020 Jun; 24(3):135-141. PubMed ID: 32648548
    [No Abstract]   [Full Text] [Related]  

  • 7. An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial.
    McMahon JH; Lau JSY; Roney J; Rogers BA; Trubiano J; Sasadeusz J; Molton JS; Gardiner B; Lee SJ; Hoy JF; Cheng A; Peleg AY
    Trials; 2020 Oct; 21(1):847. PubMed ID: 33050947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting.
    Robson F; Khan KS; Le TK; Paris C; Demirbag S; Barfuss P; Rocchi P; Ng WL
    Mol Cell; 2020 Sep; 79(5):710-727. PubMed ID: 32853546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statin therapy and SAR-COV-2: an available and potential therapy?
    Abdel-Latif RG; Mohammed S; Elgendy IY
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):333-334. PubMed ID: 32379307
    [No Abstract]   [Full Text] [Related]  

  • 10. Sofosbuvir for COVID-19 infection: A potential candidate.
    Gupta R; Dhamija P
    Indian J Pharmacol; 2020; 52(3):232-233. PubMed ID: 32874010
    [No Abstract]   [Full Text] [Related]  

  • 11. Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis.
    Shrestha DB; Budhathoki P; Khadka S; Shah PB; Pokharel N; Rashmi P
    Virol J; 2020 Sep; 17(1):141. PubMed ID: 32972430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovering drugs to treat coronavirus disease 2019 (COVID-19).
    Dong L; Hu S; Gao J
    Drug Discov Ther; 2020; 14(1):58-60. PubMed ID: 32147628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.
    Choy KT; Wong AY; Kaewpreedee P; Sia SF; Chen D; Hui KPY; Chu DKW; Chan MCW; Cheung PP; Huang X; Peiris M; Yen HL
    Antiviral Res; 2020 Jun; 178():104786. PubMed ID: 32251767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances and challenges in the prevention and treatment of COVID-19.
    Han YJ; Ren ZG; Li XX; Yan JL; Ma CY; Wu DD; Ji XY
    Int J Med Sci; 2020; 17(12):1803-1810. PubMed ID: 32714083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
    Martinez MA
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid repurposing of drugs for COVID-19.
    Guy RK; DiPaola RS; Romanelli F; Dutch RE
    Science; 2020 May; 368(6493):829-830. PubMed ID: 32385101
    [No Abstract]   [Full Text] [Related]  

  • 17. News Feature: To counter the pandemic, clinicians bank on repurposed drugs.
    Madhusoodanan J
    Proc Natl Acad Sci U S A; 2020 May; 117(20):10616-10620. PubMed ID: 32350142
    [No Abstract]   [Full Text] [Related]  

  • 18. Statins in coronavirus outbreak: It's time for experimental and clinical studies.
    Bifulco M; Gazzerro P
    Pharmacol Res; 2020 Jun; 156():104803. PubMed ID: 32289478
    [No Abstract]   [Full Text] [Related]  

  • 19. Is the type of diabetes treatment relevant to outcome of COVID-19?
    Bloomgarden Z
    J Diabetes; 2020 Jul; 12(7):486-487. PubMed ID: 32353193
    [No Abstract]   [Full Text] [Related]  

  • 20. Investigating hypothiocyanite against SARS-CoV-2.
    Cegolon L
    Int J Hyg Environ Health; 2020 Jun; 227():113520. PubMed ID: 32305009
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.